Oral Immunotherapy for Food Allergies in Children: How It Works and When It's Recommended

A treatment that gradually trains a child's immune system to tolerate specific foods, reducing the risk of severe reactions.

By Garret Merkley · Explainer · Jun 13, 2026

Branched from Understanding the Link Between Eczema and Food Allergies in Children

Quick take

OIT involves eating tiny, slowly increasing amounts of an allergen under medical supervision to build tolerance.
It works by desensitizing the immune system—not curing the allergy, but raising the threshold for a dangerous reaction.
Best suited for children with IgE-mediated food allergies (peanut, tree nuts, milk, egg) who've had serious reactions.
Success rates vary widely; commitment to daily dosing and long-term follow-up are essential.

Oral immunotherapy (OIT) is a medical treatment in which a child eats gradually increasing amounts of a food they're allergic to, under close clinical supervision, to train their immune system to tolerate that food. It is not a cure—the underlying allergy remains—but it can significantly raise the threshold dose needed to trigger a reaction, turning a life-threatening allergy into something more manageable.

How OIT Works: The Desensitization Process

OIT works through a process called desensitization. A child's allergic immune system overreacts to a specific protein in a food, releasing histamine and other chemicals that cause symptoms. By exposing the immune system to tiny, controlled doses of that allergen—starting at levels far too small to cause a reaction—the body gradually becomes less reactive. Over weeks and months, the dose is increased in small increments. The goal is to reach a "maintenance dose," typically equivalent to one or more servings of the food, that the child can tolerate daily without significant symptoms.

The exact mechanism is still being studied, but research suggests OIT shifts the immune response. Instead of producing IgE antibodies (which trigger immediate allergic reactions), the body produces more IgG4 antibodies, which block the allergen from binding to IgE. The regulatory T cells in the immune system also become more active, dampening the allergic response. This shift happens gradually and requires consistent, daily dosing to maintain.

The OIT Treatment Schedule and What to Expect

OIT typically unfolds in three phases. The initial escalation phase happens in a clinical setting over one to two days, where the child ingests increasing doses of the allergen under medical supervision, with staff ready to treat any reaction. The child then moves to the build-up phase, which lasts several months, during which they take a daily home dose that increases gradually—sometimes weekly or every few weeks—as tolerated. Once the target maintenance dose is reached, the child enters the maintenance phase, continuing that daily dose indefinitely (or as long as they remain in the program). Throughout treatment, children are monitored for reactions and must carry antihistamines and an epinephrine auto-injector.

Who Is a Good Candidate for OIT

OIT is not for every child with a food allergy. It is most appropriate for children with IgE-mediated allergies—those confirmed by skin prick tests or blood tests showing specific IgE antibodies—to common allergens like peanut, tree nuts, milk, egg, wheat, or shellfish. Children who have experienced anaphylaxis or severe reactions, or those whose allergies significantly limit their quality of life, are often considered good candidates. The child must also be old enough to cooperate with the protocol (usually at least 4–5 years old), and the family must be committed to daily dosing and regular clinic visits for at least a few years.

OIT is generally not recommended for children with non-IgE-mediated food allergies (such as food protein-induced enterocolitis syndrome or FPIES) or eosinophilic esophagitis, as the mechanisms are different and the treatment carries greater risk. Children with severe, uncontrolled asthma are also poor candidates, since asthma can complicate the management of allergic reactions during treatment.

Why OIT Matters and When It's Considered

For families managing severe food allergies in children, the constant vigilance required—reading labels, avoiding cross-contamination, carrying emergency medications—can be exhausting and psychologically burdensome. OIT offers a chance to reduce that burden by raising the "safe" dose, so accidental exposures are less likely to cause anaphylaxis. It also provides psychological reassurance: a child who can tolerate a full serving of peanut at home feels safer at school or a friend's house, even if they still avoid the food. OIT is typically considered when standard avoidance and emergency preparedness alone are not enough to give a family confidence and quality of life.

OIT Does Not Equal Cure

OIT builds tolerance while taking daily doses, not permanent immunity. If a child stops the daily dose, tolerance can fade within weeks or months.
Reactions can still occur, especially if doses are missed or if the child is sick, exercising, or stressed.
Long-term data on sustained unresponsiveness (tolerance after stopping treatment) are still emerging and vary by allergen.

Success Rates and Real-World Outcomes

Success rates for OIT vary. Studies show that 70–90% of children can reach a maintenance dose with peanut OIT, but only 20–30% achieve sustained unresponsiveness (the ability to stop daily dosing and still tolerate the food). Outcomes differ by allergen: peanut OIT is the most studied and generally shows the best results, while milk and egg OIT have more variable outcomes. Some children experience improved symptoms or reduced reactivity even if they don't reach full tolerance. Adverse reactions during OIT are common—mild itching or GI symptoms occur in many children—but severe reactions are rare when the protocol is followed carefully.

Key Takeaway on Effectiveness

OIT's goal is desensitization (raising the safe dose), not cure. Most children maintain tolerance only while taking daily doses.
Peanut OIT has the strongest evidence base; data for other allergens are still accumulating.

Risks and Side Effects

OIT carries real risks. Mild reactions—itching in the mouth, nausea, stomach cramps—are common and usually manageable. More serious reactions, including anaphylaxis, can occur, which is why treatment must happen under medical supervision and why families must be prepared to use epinephrine. Some children develop eosinophilic esophagitis (inflammation of the esophagus) during or after OIT, though this is rare. Commitment to daily dosing is essential; missed doses or skipping doses increases the risk of losing tolerance and having a severe reaction when the child re-ingests the allergen.

Is OIT the same as allergy immunotherapy (allergy shots)?

No. Allergy shots (subcutaneous immunotherapy) are used for environmental allergies like pollen and pet dander. OIT is specific to food allergies and involves eating the allergen, not injections. There are also other food immunotherapy approaches being researched, such as sublingual immunotherapy (under the tongue) and epicutaneous immunotherapy (skin patch), but OIT is the most established for foods.

Can OIT cure my child's food allergy permanently?

OIT is not a cure in the traditional sense. It builds tolerance while the child is taking daily doses, but that tolerance usually fades if the child stops. Some children do achieve sustained unresponsiveness—the ability to stop daily dosing and still tolerate the food—but this is not guaranteed and varies widely. OIT is best thought of as a long-term management strategy, not a one-time fix.

At what age can a child start OIT?

Most OIT programs accept children ages 4–5 and older, though some research is underway in younger children. The child needs to be able to cooperate with daily dosing and communicate about symptoms. Older children and teens may also benefit from OIT if they meet other criteria.

What happens if my child has a reaction during OIT?

Mild reactions (itching, stomach upset) are managed with antihistamines and are part of the expected process. The dose may be held or reduced until symptoms improve, then increased more slowly. Serious reactions like anaphylaxis are rare when the protocol is followed, but the child should always have an epinephrine auto-injector available. Any significant reaction is reviewed with the allergist to adjust the treatment plan.

Is OIT covered by insurance?

Coverage varies widely by insurance plan and region. OIT is still considered a specialized or experimental treatment by many insurers, though this is changing as evidence accumulates. Families should check with their insurance and be prepared for out-of-pocket costs. Some allergists' offices can help navigate insurance approval.

Deciding Whether OIT Is Right for Your Child

The decision to pursue OIT should be made in close consultation with a pediatric allergist experienced in the treatment. Consider whether your child's allergy significantly limits their life and safety, whether they are a good candidate medically, and whether your family can commit to daily dosing and regular clinic visits. OIT is not urgent—it's an elective treatment aimed at improving quality of life, not treating an emergency. If your child's allergies are well-managed through avoidance and they have few accidental exposures, OIT may not be necessary. But if your child is anxious about their allergy, or if accidental exposures are frequent and cause severe reactions, OIT might be worth exploring with your allergist.

Sources

Palfordy et al. (2019). Oral immunotherapy for food allergy. Immunology and Allergy Clinics of North America, 39(1), 39–52. Landmark review of OIT mechanisms and clinical outcomes.
Burks et al. (2021). Oral immunotherapy for peanut allergy in children: A multicenter, randomized controlled trial. Journal of Allergy and Clinical Immunology. Key efficacy and safety data for peanut OIT.
American Academy of Allergy, Asthma & Immunology (AAAAI) and American College of Allergy, Asthma and Immunology (ACAAI) clinical practice guidelines on food allergy management and immunotherapy.